Physician profile
Michael Yim
NPI 1194732206
$15,888.12
in general payments reported to CMS, 2019-2025
63 companies · $2,797 in 2025
The $2,797 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,372 · 2020: $1,485 · 2021: $1,665 · 2022: $1,789 · 2023: $2,454 · 2024: $3,326 · 2025: $2,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,513 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,512.92 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,928.41 | 2020-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $1,669.06 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,247.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,241.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,068.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $827.89 | 2021-2025 | Freestyle Libre 3, Eterna, Mitraclip |
| Pfizer INC. | $683.24 | 2019-2025 | |
| Lilly USA, LLC | $623.62 | 2019-2025 | Mounjaro, Kisunla, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $602.19 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $496.62 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.93 | 2019-2024 | Jardiance |
| Dexcom, INC. | $380.96 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Medtronic, INC. | $366.55 | 2022-2024 | Signia |
| Novartis Pharmaceuticals Corporation | $341.87 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $308.44 | 2021-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.